New Lifetime High Reached: Idexx Laboratories (IDXX)

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Trade-Ideas LLC identified Idexx Laboratories ( IDXX) as a new lifetime high candidate. In addition to specific proprietary factors, Trade-Ideas identified Idexx Laboratories as such a stock due to the following factors:

  • IDXX has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $32.1 million.
  • IDXX has traded 1,499 shares today.
  • IDXX is trading at a new lifetime high.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in IDXX with the Ticky from Trade-Ideas. See the FREE profile for IDXX NOW at Trade-Ideas

More details on IDXX:

IDEXX Laboratories, Inc. develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, water testing, and dairy markets worldwide. IDXX has a PE ratio of 35.8. Currently there are 5 analysts that rate Idexx Laboratories a buy, 1 analyst rates it a sell, and 2 rate it a hold.

The average volume for Idexx Laboratories has been 379,600 shares per day over the past 30 days. Idexx has a market cap of $6.4 billion and is part of the health care sector and drugs industry. The stock has a beta of 0.81 and a short float of 7% with 15.02 days to cover. Shares are up 17.1% year-to-date as of the close of trading on Tuesday.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

TheStreetRatings.com Analysis:

TheStreet Quant Ratings rates Idexx Laboratories as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, growth in earnings per share, notable return on equity, solid stock price performance and expanding profit margins. We feel these strengths outweigh the fact that the company is trading at a premium valuation based on our review of its current price compared to such things as earnings and book value.

Highlights from the ratings report include:
  • The revenue growth came in higher than the industry average of 4.0%. Since the same quarter one year prior, revenues rose by 10.8%. This growth in revenue appears to have trickled down to the company's bottom line, improving the earnings per share.
  • IDEXX LABS INC has improved earnings per share by 5.1% in the most recent quarter compared to the same quarter a year ago. The company has demonstrated a pattern of positive earnings per share growth over the past two years. We feel that this trend should continue. During the past fiscal year, IDEXX LABS INC increased its bottom line by earning $3.48 versus $3.17 in the prior year. This year, the market expects an improvement in earnings ($3.83 versus $3.48).
  • Current return on equity exceeded its ROE from the same quarter one year prior. This is a clear sign of strength within the company. Compared to other companies in the Health Care Equipment & Supplies industry and the overall market, IDEXX LABS INC's return on equity significantly exceeds that of both the industry average and the S&P 500.
  • Investors have apparently begun to recognize positive factors similar to those we have mentioned in this report, including earnings growth. This has helped drive up the company's shares by a sharp 36.52% over the past year, a rise that has exceeded that of the S&P 500 Index. Looking ahead, the stock's sharp rise over the last year has already helped drive it to a level which is relatively expensive compared to the rest of its industry. We feel, however, that other strengths this company displays justify these higher price levels.
  • The gross profit margin for IDEXX LABS INC is rather high; currently it is at 57.09%. Regardless of IDXX's high profit margin, it has managed to decrease from the same period last year. Despite the mixed results of the gross profit margin, the net profit margin of 12.21% trails the industry average.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.
null

If you liked this article you might like

Arconic, Idexx Laboratories, AbbVie: 'Mad Money' Lightning Round

Don't Get Shaken Out of Good Stocks: Cramer's 'Mad Money' Recap (Wed 9/13/17)

Resist All the Dow 22K Hoopla: Cramer's 'Mad Money' Recap (Wednesday 8/2/17)

IDEXX Laboratories: Cramer's Top Takeaways

'I Love the Down-and-Outers': Cramer's 'Mad Money' Recap (Thursday 7/13/17)